Abstract
BackgroundEpidemiological, clinical, and high-risk studies have provided evidence that the peak period for onset of diagnosable episodes of mania and hypomania starts in mid-to-late adolescence. Moreover, clinically significant manic symptoms may occur even earlier, especially in children at familial risk. Lithium is the gold standard treatment for acute mania in adults, yet to our knowledge, there is no published systematic review assessing lithium treatment of mania in children or adolescents. This is a major gap in knowledge needed to inform clinical practice.AimAs a working group within the ISBD Task Force on Lithium Treatment (http://www.isbd.org/active-task-forces), our aim is to complete a systematic review of the efficacy, tolerability, and acceptability of lithium compared with placebo and other active drugs in treating mania in children and adolescents diagnosed with bipolar disorder.MethodsWe will include double- or single-blind randomized controlled trials in patients aged less than 18 years. No restrictions will be made by study publication date or language. Several electronic databases will be searched along with secondary sources such as bibliographies and trial registry websites for published and unpublished studies. Response rates to lithium compared with placebo or other active drugs will be the primary efficacy outcome. Primary tolerability and acceptability outcomes will be rates of serious adverse events and dropouts, respectively. Secondary outcomes will include rates of remission, severity of manic symptoms at different time points, and incidence of specific adverse events.DiscussionFindings from this systematic review are critically needed to inform clinical practice. We should not generalize findings from adult studies, as children and adolescents are undergoing accelerated physiological and brain development. Therefore, efficacy, tolerability, and acceptability of lithium treatment of acute mania in children compared to adults may be very different. This systematic review has been registered in PROSPERO (CRD42017055675).
Highlights
Epidemiological, clinical, and high-risk studies have provided evidence that the peak period for onset of diagnosable episodes of mania and hypomania starts in mid-to-late adolescence
Here, lithium started earlier in the course of Bipolar disorder (BD) may have a higher likelihood of treatment response (Kessing et al 2014) and preliminary findings suggest that lithium may have neuroprotective effects (Malhi and Outhred 2016; Hajek et al 2013; Pfennig et al 2014)
As part of the ISBD Task Force on Lithium Treatment, our working group is embarking on a systematic review of studies to inform efficacy, tolerability, and acceptability of lithium treatment for acute mania in children and adolescents diagnosed with BD
Summary
Epidemiological, clinical, and high-risk studies have provided evidence that the peak period for onset of diagnosable episodes of mania and hypomania starts in mid-to-late adolescence. Lithium is the gold standard treatment for acute mania in adults, yet to our knowledge, there is no published systematic review assessing lithium treatment of mania in children or adolescents. This is a major gap in knowledge needed to inform clinical practice. As part of the ISBD Task Force on Lithium Treatment (http://www.isbd.org/active-task-forces), our working group is embarking on a systematic review of studies to inform efficacy, tolerability, and acceptability of lithium treatment for acute mania in children and adolescents diagnosed with BD
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have